Even for the therapy-naïve study cohort, differential gene expression was a significant prognosticator within tumor sets defined by their WHO grades (WHO°I: AURKB, COX10, ECT2, UBE2C; WHO°II: LEPR, MN1; WHO°III: PTTG1, UBE2C). Here, ECT2 is linked to neoplasm.